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Lung cancer is the commonest cause of cancer deaths in Western
countries. It is generally believed that cancer is the end-result of a
multistep process involving the activation of dominant oncogenes
and the inactivation of tumour suppressor genes. In 1996, the
Fragile Histidine Triad (FHIT) gene was cloned and shown to
reside in FRA3B at chromosome band 3p14.2, the most active of
the common fragile sites in the human genome (Ohta et al, 1996).
This is a very large locus which also encompasses a hereditary
renal carcinoma associated chromosome translocation breakpoint.
FHIT alterations are frequent in a variety of solid tumours and
cancer cell lines, including lung cancer (Ohta et al, 1996; Sozzi 
et al, 1996; Fong et al, 1997). We and others have previously
described a high frequency of allelic deletion and abnormal
mRNA transcripts in primary lung cancers and cell lines derived
from lung tumours (Sozzi et al, 1996; Fong et al, 1997). However,
the FHIT alterations in lung cancers have demonstrated features
not usually attributed to classical tumour suppressor genes such as
a lack of point mutations and the presence of associated wild-type
transcripts, prompting a number of investigators to query the role
of FHIT as a suppressor gene. Nevertheless, transfection of wild-
type FHIT into lung and other cancers with FHIT abnormalities
results in tumour suppression in vivo (Siprashvili et al, 1997).
Recently we have confirmed this tumour suppressor effect in 
lung cancer (Ji et al, submitted) although Otterson et al (1998)
presented results suggesting FHIT does not suppress tumour-
genicity.
Recent immunohistochemical studies have shown that loss of
Fhit expression occurs in a high proportion of primary lung carci-
nomas and precancerous lesions, a feature consistent with function
as a tumour suppressor (Sozzi et al, 1998; Tomizawa et al, 1998).
FHIT inactivation appears particularly important in the squamous
cell carcinoma subtype of lung cancers, and may be related to
smoking history (Sozzi et al, 1997a, 1998). Fhit protein may also
be absent or reduced in gastric, renal, pancreatic, and cervical
carcinomas (Greenspan et al, 1997; Baffa et al, 1998; Hadaczek 
et al, 1998; Simon et al, 1998). Immunohistochemical detection
has the advantage of detecting protein loss regardless of the under-
lying mechanism and thus represents an efficient method of identi-
fying functional protein inactivation. In this report, we studied Fhit
protein expression in a spectrum of non-small-cell lung cancers by
immunohistochemistry (IHC) and correlated these findings with
detailed clinicopathological features including tumour stage,
histological tumour type, smoking history and survival. A signifi-
cant advantage of our cohort is that these primary lung tumours
have been extensively investigated for other somatic mutational
events including 3p allele loss, particularly in the vicinity of the
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suppressor loci (Fong et al, 1994, 1995a, 1995b, 1995c, 1997).
Our aims were to determine whether loss of heterozygosity (LOH)
at the FHIT locus was associated with loss of protein expression,
to determine the prognostic significance of Fhit down-regulation, 
to confirm the association between Fhit expression and tumour
histology, and to probe for correlations with a variety of other
genetic abnormalities in this cohort of well characterized
NSCLCs.
MATERIALS AND METHODS
Patient material
Tumour blocks were obtained from 108 patients with primary
NSCLC at The Prince Charles Hospital, Brisbane, Australia who
had been treated with curative resectional surgery. This cohort of
unselected patients had previously been investigated for molecular
genetic changes at candidate chromosomal regions (Fong et al,
1994, 1995a, 1995b, 1995c, 1997). From this cohort, pathology
review (by JG) identified 99 cases where adequate material
remained for immunohistochemical evaluation. The samples were
collected from June 1990 to March 1993 and survival data of 5 or
more years were available on most patients. There were 70 males
and 29 females, with an age range of 28–81 years (mean age 61 ±
11 years at diagnosis). The patients had an overall 43 ± 32 mean
pack years of smoking (range 0–150 pack years). Independent
histological examination of the tumours was performed according
to 1982 WHO criteria and pathologically confirmed pTNM stage
was assigned in accordance with the International Union Against
Cancer. There were 56 stage I, 22 stage II and 21 stage III tumours.
Histological subtypes included 39 squamous cell carcinomas
(SCCs), 43 adenocarcinomas (including six with bronchiolo-
alveolar characteristics), 11 adenosquamous cancers, two large-
cell carcinomas, three atypical carcinoids and one typical carci-
noid. A detailed medical and smoking history was available and
there were eight never/non-smokers and 91 smokers with mean
pack years of 46 (range 1–150). This study is part of an ongoing
research project and thus data on other molecular markers were
available for analysis including: K-ras codon 12 mutations; p53
abnormalities; 3p14.2 LOH, LOH at other loci on 3p, and LOH at
known or putative tumour suppressor gene loci on 1p, 5q, 8p, 9p,
11p, 13q, 17p, 17q and 18q; and p53, RB and p16 expression by
IHC (Fong et al, 1994, 1995a, 1995b, 1995c, 1998; Geradts et al,
1999). As a positive external Fhit control, we used normal kidney.
As negative external controls, we used cell blocks prepared from
the  FHIT-deleted lung cancer cell lines NCI-H661 and NCI-
H1915 (Fong et al, 1997).
Immunohistochemistry
One representative block was retrieved for each case, and four-
micron paraffin sections were prepared and used within 72 h for
immunohistochemistry (see below) or stored at 4°C. The paraffin
sections were reacted with rabbit polyclonal anti-Fhit antibody
(generously provided by Dr Kay Huebner at the Kimmel Cancer
Center in Philadelphia, PA, USA) which had been raised against a
glutathione/S-transferase (GST)-Fhit fusion protein (Siprashvili et
al, 1997; Sozzi et al, 1997b) without a preceding antigen retrieval
step. The antibody was used at a 1:2500 dilution for 2 h at room
temperature. Non-specific rabbit serum (negative control reaction)
was used under identical conditions. The detection reaction
followed the Vectastain Elite ABC kit protocol (Vector,
Burlingame, CA, USA). Diaminobenzidene was used as
chromogen, and haematoxylin as counterstain.
Interpretation of stains
Fhit-positive cell lines and tissues were characterized by diffuse,
moderate to strong cytoplasmic staining. A tumour was considered
Fhit-positive if there was cytoplasmic reactivity in the neoplastic
cells. The tumour was scored as Fhit-negative if there was no cyto-
plasmic reactivity within the neoplasm, with preserved reactivity
in admixed non-neoplastic cells. Fhit-positive internal controls
included columnar epithelium, type II pneumocytes, alveolar
macrophages and nerves.
Statistical analysis
Statistical analysis of correlations between variables was per-
formed using either c2 test or Fisher’s exact test for categorical
data or t-test for means. Survival curves were calculated by the
Kaplan–Meier method and compared by log rank analysis using
SPSS for Windows V8.
RESULTS
Fhit expression patterns
The Fhit staining patterns clearly fell into two categories. Forty-
seven lung tumours showed cytoplasmic reactivity in the majority
of neoplastic cells, usually of moderate to strong intensity. These
were considered Fhit-positive (normal expression pattern). A
representative Fhit-positive tumour is depicted in Figure 1A. The
remaining 52 lung cancers were characterized by complete
absence of cytoplasmic staining (abnormal expression pattern).
Admixed non-neoplastic elements served as Fhit-positive internal
controls (Figure 1B).
Correlation of Fhit expression with tumour histology
We found a highly significant correlation between Fhit expression
and lung cancer histology (Table 1). Thirty-seven of 50 (74%)
NSCLCs with squamous differentiation, including 28 of 39 (72%)
SCCs and nine of 11 (82%) adenosquamous carcinomas were Fhit-
negative. In contrast, only 12 of 47 (25%) tumours with glandular
differentiation, including 11 of 38 (27%) adenocarcinomas and
one of six bronchiolo-alveolar carcinomas (BACs) (17%),
expressed Fhit. Our cohort also included two large cell carci-
nomas, one of which was Fhit-negative. The single carcinoid
tumour was Fhit-positive. In contrast, all three atypical carcinoids
had lost Fhit.
Correlation of Fhit expression with LOH at 3p14.2 and
other chromosomal loci and with K-ras codon 12
mutations
There was a correlation (P = 0.007) between loss of Fhit expres-
sion and LOH at 3p14.2, the locus of the FHIT gene, as deter-
mined by microsatellite analysis of two intragenic markers
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LOH at two more distal loci on 3p (Table 2). LOH data were
available on nine additional chromosomal arms that are the sites of
known or suspected tumour suppressor genes. There was no statis-
tically significant correlation between LOH at seven of these loci
and Fhit expression (Table 2). However, loss of Fhit was associ-
ated with LOH at the MCC/APC locus on 5q (P = 0.006) and with
LOH at the p53 locus on 17p13 (P = 0.023, Table 3). Conversely,
there was an inverse relationship between Fhit negativity and the
presence of a mutation in codon 12 of the K-ras gene (P = 0.016,
Table 3).
Correlation of Fhit expression with p53, RB and p16
protein expression abnormalities
The relationship between Fhit and p53, RB and p16 protein
expression has previously not been studied in detail. We found no
association in this cohort between Fhit immunohistochemical
staining status and expression of the three important tumour
suppressor genes p53 (P = 0.215), RB (P = 0.511) and p16 (P =
0.96). It has been suggested that there may be a correlation
between Fhit and p53 abnormalities in lung cancer (Burke et al,
1998; Marchetti et al, 1998b). In this series of NSCLCs, we had
previously studied p53 abnormalities by PCR-SSCP (polymerase
chain reaction single strand conformation polymorphism analysis)
and immunohistochemical staining (Fong et al, 1995c; Geradts et
al, 1999). While there was a correlation between Fhit negativity
and LOH at 17p13, the chromosomal p53 locus, there was no
correlation between loss of Fhit expression and mutational
analysis of p53 exons 5–8 by PCR-SSCP or p53 overexpression by
IHC (Table 3).
Correlation of Fhit expression with clinical features and
survival
In this cohort of 99 NSCLCs there was no statistically significant
correlation between loss of Fhit expression and gender, age at
presentation, smoking history, tumour size, nodal involvement and
stage of disease (Table 4). Likewise, there was no difference in
overall survival between patients with Fhit-negative and Fhit-
positive tumours (Figure 2).
DISCUSSION
FHIT abnormalities in tumours are often manifest as loss of one
allele with abnormal transcripts or deletion of the remaining allele,
whereas point mutations are rare (Sozzi et al, 1996; Fong et al,
1997; Nelson et al, 1998). Loss of expression of Fhit, the protein
product of the gene, has been described in several common types
of human neoplasia including lung cancer (Sozzi et al, 1997b,
1998; Tomizawa et al., 1998). Immunohistochemistry is particu-
larly well suited to demonstrate loss of Fhit protein expression in
the neoplastic cell population in clinically relevant materials,
whatever the underlying mechanism. In our series of 99 Australian
NSCLCs, 52 showed complete loss of cytoplasmic Fhit staining
with retention of staining in the adjacent non-neoplastic tissues
such as bronchial mucosa (Figure 1B). This frequency is between
the loss of Fhit protein expression rates previously reported by the
Japanese series of Tomizawa et al (34%) (Tomizawa et al, 1998)
and the European series of Sozzi et al (73%) (Sozzi et al, 1998).
We did not see the intermediate level of Fhit staining, as reported
by other groups in 15–20% of lung cancers (Kovatich et al, 1998;
Tomizawa et al, 1998) and as may be seen in other types of
tumours (Greenspan et al, 1997; Hadaczek et al, 1998). These
discrepancies may well be due to differences in immunohisto-
chemical techniques, stain interpretation, or different distributions
of histological subtypes (see below).
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Figure 1 Fhit expression in NSCLC. (A) Fhit-positive papillary
adenocarcinoma. Note strong cytoplasmic staining in almost all tumour cells.
(B) Fhit-negative squamous cell carcinoma. The poorly differentiated tumour
nests on the right are entirely negative. The overlying bronchial epithelium
(left) serves as an internal positive control. Original magnifications 400´
Table 1 Correlation between Fhit expression and histological tumour type in 99 non-small cell lung cancers
Squamous cell Adenosquamous Adenocarcinoma Bronchiolo-alveolar Othera Total
carcinoma carcinoma carcinoma
Fhit+ 11 (28%) 2 (18%) 27 (73%) 5 (83%) 2 (33%) 47 (47%)
Fhit– 28 (72%) 9 (82%) 10 (27%) 1 (17%) 4 (67%) 52 (53%)
Total 39 11 37 6 6 99
P < 0.001. aOther = large cell carcinoma (n = 2), carcinoid (n = 1), atypical carcinoid (n = 3).Our data add to the growing body of evidence that loss of Fhit
expression is distinctly more frequent in lung cancers with squa-
mous differentiation. In our experience, adenosquamous carci-
nomas lose Fhit expression to a similar degree as pure SCCs,
whereas BACs have a Fhit negativity rate similar to conventional
adenocarcinomas (Table 1). Two other immunohistochemical
studies also showed that squamous carcinomas were significantly
more likely to be Fhit-negative than adenocarcinomas (Sozzi et al,
1998; Tomizawa et al, 1998). In addition, it was previously shown
that LOH at the FHIT locus is less common in adenocarcinomas
compared to SCCs (Fong et al, 1997; Burke et al, 1998).
Furthermore,  FHIT abnormalities are very common in small-cell
carcinomas but relatively infrequent in pulmonary carcinoids
(Fong et al, 1997; Kovatich et al, 1998). These findings are
confirmed by our observation that Fhit expression was lost in all
three atypical carcinoids, but preserved in the single typical carci-
noid tumour. The small number of SCLCs we stained for Fhit have
all been negative (data not shown). In aggregate, the present and
previously published data indicate that FHIT abnormalities are
particularly common in those histological types of lung cancer
(such as squamous and small-cell carcinomas) that are most
closely associated with exposure to cigarette smoke.
In our series we looked for relationships between aberrant Fhit
expression and a large number of other molecular genetic abnor-
malities in NSCLC. Loss of Fhit expression was correlated with
LOH at 3p14.2, although 36% of cases were discordant (Table 2).
The presence of Fhit immunoreactivity in LOH positive cases
(14%) must reflect expression from the remaining 3p14.2 allele.
The absence of Fhit staining in tumours without demonstrable
LOH (22%) probably results from contaminating normal tissue in
non-microdissected primary tumours subjected to molecular
analysis. Similar findings were reported by others (Tomizawa et
al, 1998). In addition, Sozzi et al have shown a good correlation
between Fhit IHC and Southern, reverse transcription PCR (RT-
PCR) and Western analyses (Sozzi et al, 1997b). The positive
correlation of LOH at the FHIT locus and loss of Fhit expression is
interesting because intragenic mutations do not appear to be a
1194 J Geradts et al
British Journal of Cancer (2000) 82(6), 1191–1197 © 2000 Cancer Research Campaign
Table 2 Correlation between Fhit expression and LOH at the FHIT locus (3p14.2) and other tumour suppressor gene loci
Chromosomal locus Fhit immunohistochemistry P (c2)
(microsatellite markers) Positive Negative
3p14.2 (D3S1300, D3S4103) LOH (–) 29 20
LOH (+) 13 29
3p21 (D3S1029) LOH (–) 23 20
LOH (+) 12 12
3p25.3–26.2 (D3S1038) LOH (–) 26 26
LOH (+) 13 15
1p (L-Myc) LOH (–) 28 27
LOH (+) 7 14
5q (APC, MCC) LOH (–) 29 19
LOH (+) 4 14
8p (LPL) LOH (–) 22 23
LOH (+) 12 15
9p (IFNA, D9S126) LOH (–) 25 27
LOH (+) 14 18
11p (H-ras, INS, RRM1, LOH (–) 32 33
FSHB, WT1, CAT) LOH (+) 9 15
13q (RB, D13S260) LOH (–) 32 34
LOH (+) 14 16
17q (NF1, NM23H1, LOH (–) 27 26
D17S40, D17S21, D17S4) LOH (+) 17 20
18q (DCC) LOH (–) 33 37
LOH (+) 5 6
aWith multiple comparisons, Bonferroni’s correction was used to set the level of significance at P = 0.005.
Table 3 Correlation between Fhit expression and p53 abnormalities and
mutations in the K-ras gene
p53 status K-ras codon 12
mutation
17p13 (D17S5) LOH p53E5–8 SSCP p53 IHC
– + Wild-type Shift – + – +
Fhit + 20 13 38 9 27 19 38 9
Fhit – 10 21 37 15 24 28 50 2
P = 0.023 P = 0.261 P = 0.215 P = 0.016
0.007a
0.761
0.169
0.006a
0.715
0.699
0.324
0.869
0.641
0.917
0.784common mechanism for inactivating the second allele. It is
conceivable that loss of one FHIT allele may be associated with
genetic or epigenetic promoter inactivation in the second allele, or
with regulatory abnormalities upstream. In aggregate, these find-
ings provide evidence that the FHIT gene is a critical and specific
target in pulmonary carcinogenesis. In contrast, loss of Fhit
expression was not associated with LOH at many other known or
presumed tumour suppressor gene loci on 3p and on other chromo-
somal arms, with the possible exceptions of the APC/MCC locus
on 5q and loci on 17p13 near TP53. In addition, we found no asso-
ciation between loss of Fhit staining and loss of IHC expression of
RB and p16 or accumulation of p53. These findings suggest that
disruption of FHIT function is independent of the other major
known molecular abnormalities in lung cancer.
It was previously suggested that the genetic changes at the FHIT
locus may be correlated with p53 mutations (Burke et al, 1998;
Marchetti et al, 1998b), while other investigators found no statisti-
cally significant correlation between FHIT and p53 abnormalities
in NSCLCs (Nelson et al, 1998). In our series, loss of Fhit expres-
sion was not correlated with p53 SSCP abnormalities in exons 5–8
or p53 accumulation by IHC (Table 3). Likewise, in the immuno-
histochemical study by Sozzi et al, Fhit down-regulation occurred
at comparable frequencies in p53-positive and p53-negative
NSCLCs (Sozzi et al, 1998).
Loss of Fhit expression was significantly less common in
tumours harbouring a K-ras mutation (Table 3), suggesting that
both events are not required in the great majority of NSCLCs. This
observation is also in keeping with the selective occurrence of
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Table 4 Clinical parameters stratified by Fhit immunohistochemical
expression
Fhit immunohistochemistry P
Positive Negative
Mean age (years) 62.4 59.7 0.221a
Pack-years 36.5 48.1 0.071a
Sex
Male 29 41
Female 18 11
Smoking history
Smoker 42 49
Non-smoker 5 3
T stage
11 3 1 4
2 31 32 0.670b
33 6
N stage
02 8 3 4
1 13 11 0.751b
26 7
TNM stage
I2 7 2 9
II 11 11 0.883b
III 9 12
at-test; b c2 test; c Fisher’s exact test.
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Figure 2 Kaplan–Meier survival curve of the 99 cases of NSCLC stratified by Fhit immunohistochemical expression status. There was no significant difference
in survival curves between those tumours with and those without Fhit expression
0.061b
0.472cK-ras mutations in adenocarcinomas and with the preferential
targeting of FHIT in tumours with squamous differentiation.
Interestingly, one of the two tumours showing both loss of Fhit and
mutation of K-ras was an adenosquamous carcinoma. A lack of
correlation between FHIT exon deletion and ras mutations was
reported by Nelson et al (1998), and in heavy smokers, no signifi-
cant association between FHIT LOH and K-ras abnormalities was
demonstrable (Marchetti et al, 1998b).
In earlier work in our cohort of patients, and in two other series
(Marchetti et al, 1998a; Tomizawa et al, 1998; Geradts et al,
1999), 3p14.2 LOH at or near the FHIT locus was not associated
with impaired survival, while a fourth study (Burke et al, 1998)
described an adverse effect on survival. We found that loss of Fhit
protein expression was not significantly associated with a number
of clinical parameters including age, gender and T, N and TNM
stage, or survival (Table 4 and Figure 2). This is in agreement with
the findings by Nelson et al (1998) and Sozzi et al (1998), both of
whom also failed to detect a prognostic effect of aberrant Fhit
expression in resected NSCLCs. In contrast, Tomizawa et al
(1998) found loss of Fhit protein expression to be associated with
adverse survival specifically in stage I NSCLCs. However,
tumours with an intermediate level of Fhit reactivity were
excluded from the survival analysis. Thus, three of four studies are
consistent with a role of FHIT abnormalities at a relatively early
stage of pulmonary neoplasia, rather than in the metastatic
progression of invasive lung cancers.
It has been suggested that the FHIT gene is specifically targeted
by carcinogens in cigarette smoke, and a number of reports
described an increased frequency of FHIT abnormalities at the
DNA or protein level in smokers (Sozzi et al, 1997a, 1998;
Marchetti et al, 1998b; Nelson et al, 1998; Tomizawa et al, 1998).
Our series of 99 NSCLC patients included only eight non-
smokers, which may in part account for the lack of a statistically
significant correlation between smoking history and Fhit expres-
sion (Table 4) or LOH at the FHIT locus (Geradts et al, 1999).
However, we did find a tendency for an increase in loss of Fhit
expression with extensive cigarette consumption (P = 0.07).
In summary, our immunohistochemical analysis of Fhit expres-
sion in 99 well-characterized NSCLCs confirms that loss of Fhit
protein expression is among the most common molecular abnor-
malities in this tumour type. The positive correlation with 3p14.2
LOH further suggests that the FHIT gene is an important target for
disruption at the DNA and cDNA levels in bronchogenic carci-
nomas. The lack of association between loss of Fhit expression
and multiple other molecular abnormalities emphasizes the inde-
pendent nature of disrupting the Fhit pathway in lung carcino-
genesis. The particularly frequent loss of expression in tumours
with squamous differentiation and the inverse correlation with
K-ras mutations provides additional evidence that different histo-
logical lung cancer types are associated with particular molecular
alterations. Finally, Fhit down-regulation was not correlated with
important clinical parameters including stage and survival
suggesting that it plays a role early in the pathogenesis of lung
cancer rather than in later metastatic stages.
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